By John Miller
ZURICH, Feb 1 (Reuters) - Swiss drugmaker Roche ROG.S
expects erosion of Rituxan sales in Europe will intensify in
2018 as cheaper copies made by rivals gather momentum, its drug
unit said on Thursday.
Revenue for Roche's top-selling blood cancer medicine in
Europe plunged 26 percent in the fourth quarter of 2017, after a
16 percent third-quarter drop following patent losses.
Overall, the medicine's full-year sales rose by 1 percent to
7.4 billion Swiss francs ($7.99 billion), as sales in the
United States -- where patents remain valid until mid-2018 --
offset the European slump.
But with more Rituxan biosimilar launches from Novartis
NOVN.S and Celltrion 091990.KQ across Europe on the way,
O'Day said the decline will worsen.
"We'll see an acceleration of this exposure... all expected
in the first half of the year," Roche pharmaceuticals chief Dan
O'Day told analysts in London.
Roche on Thursday forecast U.S. tax changes would help
profit growth outstrip sales in 2018. urn:newsml:reuters.com:*:nL8N1PR0U4
But the Basel company's vulnerability to biosimilars is
growing: Beyond Rituxan, up to five biosimilar copies of Roche's
$7 billion-per-year cancer drug Herceptin could be introduced
this year, O'Day said.
Roche Chief Executive Severin Schwan acknowledged Roche's
2018 sales target-- for flat or low-single-digit percentage
growth -- is "more cautious" than in years past due to
biosimilar threat.
($1 = 0.9267 Swiss francs)
(Reporting by John Miller, editing by John Revill)
((J.Miller@thomsonreuters.com; +41 58 306 7734; Reuters
Messaging: j.miller.thomsonreuters.com@reuters.net))
Keywords: ROCHE RESULTS/BIOSIMILARS